From ordering pension forms through to pre-populating deed updates, the Partners Online Document Service allows you to completely streamline the way you order, update and manage your clients’ documents.
We are one of Australia's leading providers of business and financial advisory services for individuals, families, business owners and organisations.Learn more about us
We can help you at every life stage from starting a career, buying a home and starting a family, through to establishing a business, developing wealth creation strategies, planning for retirement and aged care solutions.
Investment solutions driven by our expert committee.
Ensuring your financial security and helping you to protect your current lifestyle, business and retirement plans.
We’ll work with you to find the most appropriate financing to suit your needs, whether you need it for your personal home, a residential or commercial investment property, refinancing or cash flow for your business.
Helping you to protect your personal wealth and business assets through smart legal solutions and estate planning advice.
Taking the complexity out of SMSF administration.
Our rigorous audit process will provide you with peace of mind that your SMSF is always compliant.
Tailored and strategic financial advice for healthcare professionals, helping you to achieve your personal and professional goals.
The team at Partners Wealth Group have always shown they will go above and beyond to get my deals done. In what has been a trying few years in property, and specifically development, Julie and the Lending team have worked tirelessly to get funding for land, construction and residual stock as well as giving my personal financial position priority to ensure the deal done is the right deal. No hesitation in recommending Partners Wealth Group.
Adam Sloane | Developer
More vaccine news as the AstraZeneca/University of Oxford candidate released interim results for two studies showing varying efficacy rates.
The rotation continues, with another vaccine candidate from Moderna indicating 94% efficacy, whilst Pfizer/BioNTech’s final study result indicating 95% efficacy, higher than the 90% from the interim analysis.
Markets were marginally lower as U.S. stimulus remains elusive and COVID-19 cases continue to rise in the U.S. and Europe. The S&P/ASX 200 fell 0.2% whilst the U.S. S&P 500 fell 0.5%.